Harnessing Herbal Wisdom against SARS-CoV-2: A Review of Plant-derived Antiviral Agents
Background: The COVID-19 Pandemic caused by SARS-CoV-2 has exposed a major gap in the global healthcare system. Although vaccines and synthetic antivirals are available, challenges such as emerging variants, limited accessibility, and uneven distribution persist. This has increased in medical plants as alternative therapeutic options. Aim: This study aims to evaluate the potential of plant phytochemicals as antiviral agents against SARS-CoV-2 and their role in integrative and future pandemic management strategies. Methods: Our systematic review of literature from 2020 to 2025 was included using databases such as PubMed, Web of Science, and Google Scholar. Focusing on antiviral, immunomodulatory and anti-inflammatory properties of medical plants and their bioactive compounds was analysed, including in silico, in vitro and clinical evidence. Results: Some phytochemical such as glycyrrhizin, curcumin, withanolides, andrographolide, baicalein, and resveratrol, demonstrated important antiviral potential. These compounds act through multiple mechanisms, including spike-ACE2 inhibition, RdRp suppression, protease inhibition, and cytokine storm regulation. In vitro and computational studies confirmed their efficacy, while emerging clinical evidence supports their role as adjuvant therapies. Nanocarrier systems and bioenhancers like piperine further improve their bioavailability and therapeutic effectiveness. Conclusion: Plant-based antiviral compounds are a promising and low-cost way to treat SARS-CoV-2 and other viral infections. However, challenges include standardisation, bioavailability, and regulation. Major Findings: Plant phytochemicals show multi-target antiviral activity against SARS-CoV-2 via inhibitor RdRp suppression and immunomodulation. Nanotechnology improves their efficacy, but clinical validation and standardisation are still needed.